Alere makes last pitch to shareholders; Cernostics hauls in $1.4M for cancer test;

@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev

@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce

@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce

@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from | Follow @MichaelGFierce

> Sequenom ($SQNM) won a clinical lab permit from the New York State Department of Health, only the second non-invasive prenatal test provider to do so after Illumina's ($ILMN) Verinata Health. More

> Cernostics has raised $1.4 million to develop a test to determine patients' risk of developing esophageal cancer. Story

> The New York Times takes an in-depth look at hip replacements around the world, charting pricing differences between the U.S. and Europe and the booming industry that built Zimmer ($ZMH), Biomet and other giants. Feature

> Alere ($ALR) is just two days away from a shareholder vote that could change the direction of the company, and management sent a final letter to investors urging them to elect its board nominees. Letter

> Life Technologies ($LIFE) has teamed up with RainTree Oncology Services to make the latest advances in molecular diagnostics more available to patients around the world. News

Biotech News

@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech

@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce

@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce

> The FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report

> Bayer aims at hot cancer immunotherapy race with $540M R&D deal. News

Pharma News

@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce

@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce

> J&J slapped with HHS subpoena on Nucynta marketing. Story

> India hits Roche's Herceptin in latest blow to Big Pharma patents. More

> Drug shortage complicates execution schedule for death penalty leader Texas. Article

CRO News

> Charles River boosts sales as charges drag profits. Article

> INC expands in Japan as local market soars. Story

> Clinipace reaches into the north with CRO partnership. Item

> Quintiles posts flat revenue as charges swallow profits. Report

> Covance swings to profit despite tough early-phase market. More

> KKR buying RPS, planning to merge it with PRA. Article

Biotech IT News

> China pharma R&D drives expanded use of Medidata software. News

> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More

> Accelrys to ax 80 jobs after drop in quarterly profits. News

> Battle against breast cancer goes open source. Story

> Ex-Yahoo CEO backs genomics big data startup Bina. Article

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.